Pfizer expects 2024 revenue between US$ 58.5 to US$ 61.5 billion

Anticipates approx. US$8 billion in revenues for Comirnaty and Paxlovid

Pfizer receives regulatory approvals to complete the acquisition of Seagen

Announces changes in the commercial organization to incorporate Seagen and improve focus, speed and execution

Vertex and CRISPR Therapeutics announce USFDA approval of Casgevy for treatment of sickle cell disease

Approximately 16,000 patients 12 years of age and older with severe sickle cell disease may now be eligible for this one-time treatment

Operations disrupted at NATCO Pharma's Manali, Chennai factory

NATCO temporarily shut down the operations due to cyclone with flooding/water logging of the factory premises

AbelZeta Pharma, AstraZeneca to co-develop a novel GPC3 armored CAR-T therapy in China

C-CAR031 is based on a novel GPC3-targeting CAR-T (AZD5851) designed by AstraZeneca using their transforming growth factor-beta receptor II

Roche expands hepatitis diagnostics portfolio

Almost 300 million people globally have chronic hepatitis B

BrainSpec receives FDA clearance to begin using AI-backed solution for non-invasive brain chemistry measurement

First-ever brain chemistry database will allow clinicians to quickly infer brain biomarker data to support the diagnostic process in conditions such as Alzheimer's Disease

DxVx plans to make a license-in agreement of OVM-200

Final stage in licensing OVM-200 from Oxford Vacmedix in the UK

AstraZeneca Pharma India receives permission to Import formulations of new drug for sale

The receipt of this permission paves way for the launch of Olaparib film coated tablets in India

Evive Biotech and Acrotech Biopharma receive FDA approval of Ryzneuta